The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

In an 8-7 vote, an internal FDA review board voted to allow Avandia to stay on the market. The vote was so close it has drawn scrutiny and criticism from Senator Charles Grassley of the Senate Finance Committee. Grassley criticized the FDA for not making public the findings of the FDA review board. Avandia, a diabetes drug, has been linked to an increase in heart attacks. Avandia already carries the black box warning, the strongest available.

For more information on this subject, please refer to the section on Drugs, Medical Devices, and Implants.

Comments are closed.

Of Interest